News and Breakthroughs
Read the latest news from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The links below take you to articles where you can learn more about our center's latest events and accomplishments. You can also visit the article archive for older news. Visit our Photo Gallery to view photos and videos from various events
High resolution electron microscopy imaging shows how damage-sensing proteins recognize DNA breaks and then bridge them together
Northwestern Medicine investigators have discovered how a particular type of immune cell exerts a dual function in cancer cells that is contingent on tumor grade.
Based on a clinical trial led by Lurie Cancer Center member Riad Salem, MD, the FDA recently approved TheraSphere Y-90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma.
Inhibiting production of a key material produced by the mTOR pathway could slow tumor growth, according to a recent Northwestern Medicine study.
Inhibiting a novel protein variant within glioma stem cells may be a promising therapeutic approach to treat glioblastoma, according to a recent Northwestern Medicine study.
In 2020, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University was one of 12 cancer centers selected to receive a grant from the National Cancer Institute (NCI) to support Interdisciplinary Research on Cancer and Aging.
A novel integrative computational technique allowed scientists to classify disease conditions at the molecular level using epigenomic data sets.
Northwestern Medicine investigators have discovered that inhibiting tumor-associated myeloid cells ability to produce specialized metabolites called polyamines may improve the effectiveness of treatments for glioblastoma.
Northwestern Medicine scientists have engineered a novel antibody that revitalizes immune cell activity in a deadly brain cancer, according to a recent study.
The Lurie Cancer Center is pleased to announce several new leadership appointments, effective April 1, 2021
Emmy Award-winning journalist and cancer survivor, Dina Bair, knows that personal stories can have the greatest impact. The WGN-TV News anchor and medical reporter is sharing her experience to honor her late father’s memory and support the Cancer Survivorship Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
An early clinical trial found that a spherical nucleic acid drug developed at Northwestern kills tumor cells in people with the fatal brain cancer glioblastoma. This is the first time a nanotherapeutic has been shown to cross the blood-brain barrier and cause cell death. Lead investigator Priya Kumthekar, MD, explains the results of the study.
An experimental spherical nucleic acid drug developed by Northwestern scientists was able to penetrate the blood-brain barrier and trigger the death of glioblastoma cells.
When Candace Henley was diagnosed with colorectal cancer in 2003, she was a 35-year-old single mother raising five daughters. As a Black woman, she found herself feeling as though she was falling through the cracks in the healthcare system.
Seema Khan, MD, and Yuan Luo, PhD, presented their research on “Computational Phenotyping to Ascertain Breast Cancer Recurrence,” by framing their lecture with a problem; the lack of accessible or existing data about breast cancer recurrence.
Award recipients are nominated by their colleagues and teammates for their skill, medical knowledge, and for going above and beyond expectations to provide exceptional and compassionate cancer care.
Perioperative chemotherapy treatment did not improve overall survival for patients with resectable pancreatic cancer, according to a recent Northwestern Medicine clinical trial.
Blocking the arginine methylation pathway, which helps brain tumor cells proliferate by promoting cell division, could improve cancer therapies, according to a recent study.
Capability could accelerate the development of new treatments for diseases
Northwestern Medicine investigators have identified a protein kinase called DYRK1A and its downstream substrates as potential therapeutic targets for treating pediatric patients with B-cell acute lymphoblastic leukemia.
See more news in the article archive.